An article published in “Anticancer Research” using our FITC Apoptosis Detection Kit by our customers from the Wrocław University of Environmental and Life Sciences, Poland and Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, in the analysis of how Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis. Congrats and Thanks.
Summary:
Targeting
the extrinsic apoptotic pathway is an interesting option for anticancer
therapy. A protein which such ability is Apo2 ligand, also known as TNF-related
apoptosis-inducing ligand (TRAIL). The aim of this study was to examine the
possibility of sensitizing resistant CLBL-1 canine lymphoma cells to
TRAIL-induced apoptosis by using flavopiridol (FVP) a cyclin-dependent kinase
inhibitor (CDKs). Materials and Methods: The CLBL-1 (canine B-cell lymphoma
cell line) was used in the study. The effect of FVP and TRAIL treatment on
apoptosis induction was assessed by flow cytometry and western blot. Results:
Although canine lymphoma cells were resistant to TRAIL-induced apoptosis,
combination of this death ligand with FVP was able to overcome TRAIL resistance
of CLBL-1 lymphoma cells. Conclusion: Our results demonstrated that although
canine lymphoma cells were resistant to TRAIL-induced apoptosis, combination of
this death ligand with FVP was able to overcome TRAIL resistance of CLBL-1
lymphoma cell line. Although further investigation is required to deepen the
knowledge of TRAIL as an antitumor agent in canine cancers, our results open
the door to future use of TRAIL-based treatment strategies in veterinary
oncology.
Reference:
Products link:
FITC Apoptosis
Detection Kit
No comments:
Post a Comment